Brokerages Set HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) PT at $20.88

Shares of HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) have earned an average rating of “Hold” from the six analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have given a hold rating, one has assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $20.8750.

HCM has been the topic of several research analyst reports. Jefferies Financial Group raised HUTCHMED to a “strong-buy” rating in a research note on Monday, January 19th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of HUTCHMED in a research note on Thursday, January 22nd. Finally, Wall Street Zen raised HUTCHMED from a “hold” rating to a “buy” rating in a report on Sunday, November 16th.

Hedge Funds Weigh In On HUTCHMED

Several institutional investors and hedge funds have recently modified their holdings of HCM. Blue Trust Inc. grew its stake in HUTCHMED by 131.5% in the 4th quarter. Blue Trust Inc. now owns 7,708 shares of the company’s stock worth $103,000 after acquiring an additional 4,378 shares during the period. Vanguard Personalized Indexing Management LLC grew its holdings in HUTCHMED by 23.2% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,490 shares of the company’s stock valued at $233,000 after purchasing an additional 2,916 shares during the period. Ameriprise Financial Inc. boosted its holdings in shares of HUTCHMED by 4.7% in the 2nd quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock valued at $234,000 after purchasing an additional 698 shares during the last quarter. Bank of America Corp DE raised its position in shares of HUTCHMED by 17.3% in the 2nd quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock worth $310,000 after buying an additional 3,035 shares during the period. Finally, Dimensional Fund Advisors LP lifted its stake in shares of HUTCHMED by 34.2% in the 3rd quarter. Dimensional Fund Advisors LP now owns 21,721 shares of the company’s stock valued at $342,000 after purchasing an additional 5,538 shares in the last quarter. Hedge funds and other institutional investors own 8.82% of the company’s stock.

HUTCHMED Trading Up 4.2%

Shares of HCM stock opened at $15.18 on Thursday. The business’s fifty day moving average price is $14.33 and its 200 day moving average price is $15.29. The company has a quick ratio of 4.51, a current ratio of 4.65 and a debt-to-equity ratio of 0.05. HUTCHMED has a 1-year low of $11.51 and a 1-year high of $19.50.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.